# TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.

> **NCT03216668** · PHASE3 · UNKNOWN · sponsor: **Nhat Nhat Pharmaceutical Company** · enrollment: 140 (estimated)

## Conditions studied

- Liver Function Failure

## Interventions

- **DRUG:** TONKA
- **DRUG:** LEGALON

## Key facts

- **NCT ID:** NCT03216668
- **Lead sponsor:** Nhat Nhat Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-15
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2018-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216668, "TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03216668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*